• news

Selected as a finalist for the KLSAP (Kansai Life Science Accelerator Program)

Celaid Therapeutics has been selected as one of the 10 finalists for the KLSAP (Kansai Life Science Accelerator Program), an acceleration program sponsored by the City of Kobe and major pharmaceutical companies.
The top three companies selected to participate in KLSAP's pitch events will be eligible to participate in a program that provides various types of support from investors and entrepreneurs in California, US

<KLSAP Pitch Event>
- July 2, 2022 (Saturday), 13:00-18:30
- Online
- Viewing is free

KLSAP Website

Copyright© セレイドセラピューティクス - 細胞治療(造血幹細胞) , 2024 All Rights Reserved Powered by STINGER.